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Abstract
Background: Venous thromboembolism (VTE) occurs when blood clots in the leg, pelvic or other
deep vein (deep vein thrombosis) with or without transport of the thrombus into the pulmonary
arterial circulation (pulmonary embolus). VTE is common in patients with cancer and is increased
by surgery, chemotherapy, radiotherapy and disease progression. Low molecular weight heparin
(LMWH) is routinely used to treat VTE and some evidence suggests that LMWH may also have an
anticancer effect, by reduction in the incidence of metastases. The FRAGMATIC trial will assess
the effect of adding dalteparin (FRAGMIN), a type of LMWH, to standard treatment for patients
with lung cancer.
Methods/Design: The study design is a randomised multicentre phase III trial comparing standard
treatment and standard treatment plus daily LMWH for 24 weeks in patients with lung cancer.
Patients eligible for this study must have histopathological or cytological diagnosis of primary
bronchial carcinoma (small cell or non-small cell) within 6 weeks of randomisation, be 18 or older,
and must be willing and able to self-administer 5000 IU dalteparin by daily subcutaneous injection
or have it administered to themselves or by a carer for 24 weeks. A total of 2200 patients will be
recruited from all over the UK over a 3 year period and followed up for a minimum of 1 year after
randomisation. Patients will be randomised to one of the two treatment groups in a 1:1 ratio,
standard treatment or standard treatment plus dalteparin. The primary outcome measure of the
trial is overall survival. The secondary outcome measures include venous thrombotic event (VTE)
free survival, serious adverse events (SAEs), metastasis-free survival, toxicity, quality of life (QoL),
levels of breathlessness, anxiety and depression, cost effectiveness and cost utility.
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Lung cancer and thromboembolism
In the UK about 33,000 patients are diagnosed with lung
cancer every year, with a median 1-year survival of 20%
[1]. The death rate from lung cancer in the western world
ranges from 5 to 27 per 100,000 per year in women and
25 to 77 per 100,000 per year in men [2,3]. Therapeutic
advances over the last 30 years have had only a modest
impact on overall survival and there is unlikely to be a
marked improvement in survival rates in the coming years
even in patients with resectable disease. There is therefore
a clear need to investigate new approaches [4].
Venous thromboembolism (VTE) is common in patients
with any cancer and the incidence is increased by surgery,
chemotherapy, radiotherapy and disease progression [5-
8]. This results in a prevalence of clinically apparent VTE
of up to 15% [9] across all cancer patients and over 50%
of palliative care inpatients [10]. Analysis of US Medicare
data suggests that the risk varies with tumour type [11].
Comparable figures are not available specifically for lung
cancer patients, but because many have advanced disease
at presentation, the prevalence of VTE is likely to be high.
Many patients with lung cancer also have co-morbidities,
such as heart failure and chronic lung disease, which also
increase the risk of VTE by 20% [12].
Buccheri et al [13] studied 286 consecutive patients with
lung cancer and found that pre-treatment abnormalities
of coagulation were significantly correlated with survival.
Large retrospective studies have also shown that the prob-
ability of death within 6 months in cancer patients with
VTE is 0.94, compared to 0.4 in those without VTE (p =
0.001) [6]. Seitz and co-workers found that lung cancer
patients with increased levels of thrombin-anti-thrombin
complex (TAT complex) in plasma seemed to have a
poorer prognosis than patients with normal levels [14].
Registry data also show that 1-year survival in cancer
patients with a VTE is 3 times less than in those without
VTE [15].
Low molecular weight heparin (LMWH) has been used for
over 20 years in the prophylaxis of VTE and has been
shown to be the drug of choice in the treatment of VTE in
cancer patients [16]. However, there are limited data on
the use of LMWH in primary thromboprophylaxis in can-
cer patients and this is reflected in the difference in prac-
tice amongst oncologists [17]. A recent survey showed
that more than 25% of British oncologists do not recog-
nise the thrombogenic effects of treatment for cancer and
that thromboprophylaxis is rarely used [18].
In view of the known pro-thrombotic state of lung cancer
and the potential antitumour effects of LMWH there is a
clear need to assess the impact that long term LMWH has
on overall survival in lung cancer patients.
Prothrombotic state in cancer
Virchow's triad states that conditions predisposing to
thrombosis include pathological changes in blood flow,
the vessel wall, and coagulability of the blood--all three of
which exist in patients with cancer. Proposed mechanisms
to explain the hypercoagulability of the blood associated
with cancer include both non-specific factors related to
the host's response to the tumour and tumour cell-specific
causes. Non-specific factors include altered coagulation
factor levels and activity, new blood vessel formation
(angiogenesis and neovascularisation of the growing
tumour mass), cell necrosis, and altered haemodynamics
related to obstruction of vessels by the tumour itself.
Examples of factors related to properties specific to the
transformed cell include expression of activators of
thrombin-generating and plasminogen activator-initiated
enzymatic pathways, and interaction with host cells,
including monocytes, platelets, and endothelial cells
[19,20].
Most patients with cancer have blood coagulation test
abnormalities indicative of up-regulation of the coagula-
tion cascade, increased platelet activation and aggrega-
tion, and increased proteolysis. The complex mechanisms
responsible for this activation may include release of can-
cer procoagulants, activation of host cells (such as mono-
cytes or endothelial cells), overexpression of plasminogen
activator inhibitor-1 (PAI-1), and altered expression or
activity of proteins produced by the liver, including pro-
tein C and anti-thrombin (AT) [20,21].
The best characterised tumour cell initiator of the coagu-
lation cascade is tissue factor (TF), a cell membrane recep-
tor for coagulation factor VII that triggers the extrinsic
coagulation pathway by formation of the TF/VIIa/Xa com-
plex. A less well characterised tumour cell activator of
coagulation is cancer procoagulant, a cysteine protease
that activates factor X. Tumours characteristically promote
excessive or unregulated angiogenesis by stimulating the
activation, adhesion, migration, proliferation, and trans-
migration of endothelial cells across tissue matrices. The
numerous interactions between coagulation activation
and angiogenesis indicate that the latter is an integral part
of the prothrombotic state in cancer [20,22-24].
Chemotherapeutic agents may also contribute to hyperco-
agulability by enhancing the release of procoagulants and
cytokines from tumour cells, producing toxic substances,
such as oxygen free radicals, that can damage the endothe-
lium, and reducing levels of natural anticoagulants, such
as proteins C and S, and AT. Surgery, which is first-line
therapy for 15-20% of lung cancer patients, is also well
known to activate the haemostatic system. In so doing,
cancer therapies initiate the coagulation cascade, promot-
ing thrombosis and tumour growth and producing unfa-
vourable outcomes [8,19].Page 2 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:355 http://www.biomedcentral.com/1471-2407/9/355Effects of heparins on cancer
A growing body of data suggests that adjunctive therapy
with heparin may improve prognosis in cancer patients.
Important information has been derived from studies on
the treatment of VTE in the general population with differ-
ent types of anticoagulants. The standard treatment of VTE
is a course of heparin followed by an oral vitamin K antag-
onist. Considering the subgroup of cancer patients with
VTE, a meta-analysis found an improved survival in can-
cer patients treated initially with LMWH when compared
with those treated with unfractionated heparin (UFH)
[25]. In the 629 cancer patients treated (306 LMWH vs
323 UFH), the pooled odds ratio for 3 month mortality
was 0.61 (95% confidence interval 0.4-0.93) in favour of
LMWH. In these studies a wide variety of cancer subtypes
were present. While this trial did not control for impor-
tant cancer prognostic variables, such as tumour type and
standard treatment, it provided an impetus for researchers
to continue investigating heparin's potential as an antine-
oplastic agent.
A randomised clinical trial of heparin as anticancer ther-
apy was conducted with 277 patients with small cell lung
cancer (SCLC) by Lebeau et al [26]. The researchers
reported that the complete response (CR) rate was signif-
icantly greater in the group receiving chemotherapy plus
subcutaneous unfractionated heparin (UFH), compared
with chemotherapy alone (37% vs. 23%, respectively;
P = 0.004). The median survival was also significantly
longer in the UFH group (317 vs. 261 days, respectively;
P = 0.01).
The effectiveness of LMWHs in SCLC was evaluated more
recently by Altinbas et al [27]. In this trial, 84 patients
with SCLC were randomised to receive either chemother-
apy (cyclophosphamide, epirubicin, and vincristine,
(CEV) or CEV plus LMWH (dalteparin)). At 18 weeks, the
overall response rate was higher in patients receiving
LMWH plus chemotherapy, compared with chemother-
apy alone (69.2% vs. 42.5%, respectively; P = 0.007).
Moreover, the duration of progression-free survival was
significantly longer with the addition of LMWH (10
months vs. 6 months with chemotherapy alone). This was
a small study of only 84 patients and the survival rate in
the control arm to chemotherapy was very low.
FAMOUS was the first prospective, randomised, placebo-
controlled trial to examine possible effects of LMWH ther-
apy (dalteparin) on survival in patients with various can-
cers without underlying thrombosis [28]. A total of 382
patients were randomised to receive either 5000 anti-Xa
units of dalteparin daily (via injection) or placebo (saline)
along with standard cancer therapies. Survival estimates
for the dalteparin and placebo group patients at 1 year
were 46% (95% CI, 39% to 53%) and 41% (95% CI, 34%
to 49%), respectively (p = 0.19). The survival rate at 2
years after randomisation was 27% (95% CI, 20% to
34%) for patients receiving dalteparin versus 18% (95%
CI, 11% to 25%) for patients receiving placebo. At 3 years
the survival rate was 21% (95% CI, 14% to 28%) for
patients in the dalteparin group and 12% (95% CI, 5% to
19%) in the placebo group. However, analysis of a group
of patients (not defined a priori) with a better prognosis
and who survived beyond 17 months found that LMWH
treatment was associated with a significant increase in sur-
vival at 25 and 36 months. The investigators concluded
that while LMWH therapy did not produce an immediate
survival benefit, it may offer an advantage in "better prog-
nosis" patients suggesting an effect on disease progression
or metastatic spread.
Antitumour effects of heparins on cancer
A variety of mechanisms have been proposed to explain
the effects of heparin on tumours [20,24,29-32]. These
mechanisms can be broadly classified as direct antitu-
mour effects, antiangiogenic effects, and immune modu-
latory effects. Therapeutic heparin may influence tumour
cell growth because of its chemical resemblance to cell
surface-associated and extracellular matrix (ECM)
heparin-like glycoaminoglycans. These molecules regu-
late the way in which cells perceive their environment by
interacting with growth factors, enzymes, chemokines,
and matrix proteins at the interface of the cell and extra
cellular matrix so as to modulate signal transduction and
thereby regulate malignant cell growth. Under certain
experimental conditions, heparin may also induce apop-
tosis and differentiation of neoplastic cells. Work in exper-
imental models has demonstrated that heparin regulates
the expression of certain oncogenes, including c-myc and
c-fos [33,34].
The antiangiogenic effects of heparin probably play a cen-
tral role in its potential use as an antineoplastic agent.
These effects appear to be unrelated to the anticoagulant
actions of the compound. The evidence suggests that
heparin acts by stabilising angiogenic growth factors
stored in the ECM.
The effects of heparin on the coagulation cascade include
the inhibition of factor IIa, inhibition of TF expression,
and activation of Tissue Factor Pathway Inhibitor (TFPI),
which down-regulates the activity of TF and factors VIIa
and Xa (the extrinsic coagulation pathway). In addition,
heparin promotes the release of tissue plasminogen acti-
vator and PAI-1 from endothelial cells, facilitating fibri-
nolysis.
There is great interest in exploring the effects of LMWHs
on blood vessels and this interest has focused on the role
of TFPI in both thrombosis and noncoagulant processes.Page 3 of 9
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describe the broad range of TFPI actions. Some of those
studies are described below.
Vascular endothelial growth factor (VEGF) is a potent
proangiogenic molecule produced by a variety of cell
types. Tissue factor pathway inhibitor can modulate the
metastatic processes induced by pathological angiogen-
esis, by blocking both the coagulant and noncoagulant
activities of the TF/VIIa/Xa complex [20,24,35]. In a study
using a chick chorioallantoic membrane (CAM) model of
human colon cancer, the administration of tinzaparin 24
hours after stimulation of angiogenesis by VEGF returned
the angiogenesis index to levels comparable to untreated
controls [20].
Similar effects of tinzaparin were observed when colon
carcinoma (HCT-116) was used to stimulate angiogen-
esis. Additional research showed an approximately 80%
reduction in the growth of colon cancer and fibrosarcoma
1 week after giving a single 0.1 mg dose of tinzaparin in
the CAM tumour implant model [36]. The investigators
concluded that tinzaparin may play an important role in
slowing tumour growth and metastasis by stimulating the
production of endothelial TFPI.
A third study looked at platelet count, a sensitive marker
of intravascular coagulation and useful indicator of
tumour-induced clotting activation. Using an animal
model of lung metastasis, Mousa et al observed that the
number of platelets fell rapidly and significantly (by
nearly 50%) after the injection of tumour cells [20]. This
effect was almost completely reversed by tinzaparin. With
daily administration of tinzaparin over the next 14 days,
the number of lung metastases was reduced by 96% rela-
tive to controls. No bleeding problems were observed.
The different antitumour effects of LMWH are likely to
vary according to the molecular weight of the drug.
Endothelial cell proliferation inhibition increases as the
size of the molecule decreases, with optimal effects
between 4.5 and 6.5 kDa [35], whilst TFPI release
increases with an increase in molecule size [37].
Choice of heparin and dose in the trial
Dalteparin is a low molecular weight heparin with anti-
thrombotic properties demonstrated by enhancing the
inhibition of Factor Xa and thrombin, by anti-thrombin.
It potentiates preferentially, the inhibition of coagulation
Factor Xa, while only slightly affecting activated partial
thromboplastin time (APTT). It is commercially available
in over 40 countries. As well as its anticoagulant and anti-
thrombotic properties, dalteparin has been shown to
inhibit tumour metastases in in vitro and in vivo studies.
Dalteparin is known to inhibit heparinase, an enzyme
that is secreted by cancer cells and takes part in the degra-
dation of the extracellular matrix. Heparinase activity cor-
relates with the metastatic potential of mammary
adenocarcinoma cells and other cell lines [34,35,37-39].
Since there is no clinical information about dalteparin
dosing and antitumour effects, the dose of dalteparin in a
study evaluating survival and prophylaxis of thromboem-
bolism should be based on the overall safety profile and
efficacy in thromboprophylaxis. The incidence of throm-
bosis in cancer patients is variable and appears to be
dependent on a number of factors including diagnosis,
stage of disease, and therapy administered. Thrombo-
prophylaxis with dalteparin 5,000 IU once daily is
approved in many countries in high-risk patients under-
going surgical procedures and acutely unwell medical
patients. In one study of surgical prophylaxis in patients
with cancer, a dose of 5,000 IU was superior to 2,500 IU
in cancer patients in terms of thromboprophylactic effi-
cacy and was not associated with an increased risk of
severe bleeding [40]. A dose of 5000 IU/day, therefore,
has demonstrated efficacy with an acceptable safety pro-
file for patients with lung cancer.
Main research question
The main study aim of the FRAGMATIC trial is to assess
the effect on overall survival of adding Low Molecular
Weight Heparin, dalteparin (FRAGMIN®) for 24 weeks to
standard treatment for patients with lung cancer. We will
also examine the impact of dalteparin on venous throm-
botic event (VTE) free survival, serious adverse events
(SAEs), metastasis-free survival, toxicity, quality of life
(QoL), levels of breathlessness, anxiety and depression,
cost effectiveness and cost utility. In this paper we describe
the study protocol.
Methods/Design
Study Design
FRAGMATIC is an open-label two arm randomised con-
trolled trial. It is being run in approximately 120 partici-
pating centres throughout the UK with the aim of
recruiting 2200 participants, 1100 participants in each
arm. At randomisation participants are assigned to either
the control arm (no dalteparin) or the research arm (daily
dalteparin). See Figure 1. All participants will receive
standard anticancer treatment of any type including sup-
portive care. Participants on the research arm will also
receive a daily dose of 5000 IU (0.2 ml) of dalteparin for
24 weeks, which will be injected subcutaneously by the
participant or a nominated carer.
FRAGMATIC has been ethically approved by the Research
Ethics Committee for Wales and has approval from the
Medicines and Health Care Product Regulatory Agency to
be conducted in the UK. The Wales Cancer Trials Unit, aPage 4 of 9
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Trial SchemaFigure 1
Trial Schema.
Consent and randomisation within 6 
weeks of tissue diagnosis (pathological 
report date) and before the start of 
treatment
Patients with histopathologically or 
cytologically confirmed primary lung 
cancer of any stage or histology
CONTROL ARM 
Ant icancer t reatment  
according t o local pract ice  
(NO DALTEPARI N)  
 
Randomise
RESEARCH ARM 
Ant icancer t reatment  according 
t o local pract ice and START 
DALTEPARI N as soon as possible 
and before f irst  def init ive 
ant icancer t reatment  (1 x daily 
dalt epar in 5,000 I U 
subcutaneous for  24 w eeks)  
Follow -up
Every 3-4 weeks from 
randomisation until the 24 week 
visit, then at 9 months and 1 year 
and at routine follow-up 
appointments thereafter
Primary out come measure of  t he t r ial is overall survival
Secondary out come measures are: 
Venous thrombotic event free survival 
 Serious adverse events 
 Metastasis-free survival 
 Toxicity 
 Quality of life 
 Breathlessness 
 Anxiety and depression 
 Cost effectiveness 
 Cost utility 
BMC Cancer 2009, 9:355 http://www.biomedcentral.com/1471-2407/9/355Cancer Research UK core funded and National Cancer
Research Institute accredited Clinical Trials Unit, is coor-
dinating the trial. Velindre NHS Trust is the sponsor for
the trial. A Trial Steering Committee and an Independent
Data Monitoring Committee has been set up to monitor
the progress and safety of the study. The FRAGMATIC Trial
Management Group, including clinicians, clinical trial
unit staff, patient representatives, nursing and pharmacy
representatives, carry out the day-to-day running of the
trial.
Participant Eligibility
Eligible participants are approached within a hospital set-
ting within 6 weeks of their lung cancer diagnosis. Partic-
ipants are screened for eligibility by research staff to
ensure all inclusion and exclusion criteria are met. For
inclusion and exclusion criteria see Table 1. Before ran-
domisation participant eligibility is confirmed within 6
weeks of their diagnosis with histology or cytology, and a
formal staging assessment. A full blood count, urea, elec-
trolytes, liver function test, corrected calcium, creatinine
and clotting profile will be performed 2 weeks before ran-
domisation. After written informed consent has been
obtained a baseline assessment of toxicity and dyspnoea
score is taken by research staff and participants must com-
plete the baseline Quality of Life and Hospital Anxiety
and Depression Scale (HADS) questionnaires. Partici-
pants are then randomised to one of the trial arms.
Sample Size Considerations
This study aims to demonstrate that dalteparin will
improve the 1-year survival of lung cancer patients by 5%.
Although the median 1-year survival for all lung cancer
patients in the UK has been shown to be 20% [1], it is
likely that those with a very short life expectancy will not
be entered into this study. For this group of patients it is
assumed that the 1-year survival in the control group is
25%. To detect an advantage in 1 year survival of 5% with
dalteparin (to 30%) a hazard ratio of approximately 0.87,
using a 2-sided log rank test with 89% power at a 5% sig-
nificance level, requires a total of 2047 events (deaths).
Accruing 2200 patients (1100 in each group) over 3 years
with a further 1 year follow-up should be sufficient to
achieve this required number of events [41]. Through dis-
cussions with the UK lung cancer clinical community and
patient representatives it was deemed that, balancing the
additional expense, risk of toxicity and logistics of giving
dalteparin, an increase of 5% in 1 year survival was clini-
cally significant. The current rate of VTE ante mortem is
15%, with a post mortem VTE rate in excess of 50% in
advanced cancer. The use of thromboprophylaxis could
therefore have a larger impact on survival.
Method of Randomisation
Patients are randomised centrally by the Wales Cancer Tri-
als Unit using the method of minimisation which
includes a random element. Patients are stratified for a
number of clinically important stratification factors. The
randomisation allocation ratio for control: research arm
will be 1:1.
Outcome Measures
The primary outcome measure is overall survival. Overall
survival is calculated from the date of randomisation, to
death from any cause. Those patients still alive will be cen-
sored at the date last seen.
The secondary outcome measures are: VTE-free survival,
metastasis-free survival, toxicity, QoL, dyspnoea, anxiety
and depression, cost effectiveness and cost utility.
VTE-free survival will be calculated from the date of ran-
domisation to the date of first clinical evidence of VTE or
death from any cause (whichever is the earlier). VTE-free
survivors will be censored on the date last known to be
alive and free of clinical evidence of a VTE. Metastasis-free
survival will be calculated from the date of randomisation
to the date of first clinical evidence of metastatic disease or
death from any cause (whichever is the earlier) in those
patients whose baseline staging indicates no evidence of
metastases at the time of randomisation. Metastasis-free
survivors will be censored on the date last known to be
alive and free of clinical evidence of metastatic disease.
Toxicity will be assessed according to NCI Common Ter-
minology Criteria for Adverse Events version 3.0 and any
serious adverse events (SAE) are collected in 'real time'.
QoL questionnaires will be completed by patients at base-
line, 12 weeks, 24 weeks, 9 months and 1 year. QoL will
be generally assessed using EQ-5D which includes a core
of five domains (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) with three options
per domain. A unique EQ-5D health state is defined by
combining the scores from each of the 5 dimensions to
produce a score from 0 to 1. The impact of dyspnoea
(breathlessness) will be assessed using the Cancer Dysp-
noea Scale, which consists of twelve items with five
options. These items are combined to create three factors
that represent the sense of effort, anxiety and discomfort.
The impact on mental health (anxiety and depression)
will be assessed using the Hospital Anxiety and Depres-
sion Scale (HADS), which consists of fourteen items with
four options, which are summed to create two subscales
'depression' and 'anxiety'. Cost effectiveness of dalteparin
will be assessed. Costs will be monitored prospectively via
Case Report Forms (CRF) for 1 year or until death, which-
ever is soonest. Survival will be adjusted for quality of life
using the EQ-5D.
Data collection
Participants will be seen at hospital every 3-4 weeks until
24 weeks after randomisation, follow up visits will occur
at months 9 and 12, and then at yearly intervals. ResearchPage 6 of 9
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CRFs which record evidence of primary and secondary
outcome measures.
Statistical analysis
All analyses will be performed on a full intention-to-treat
basis, i.e. all patients randomised will be included, and all
patients will be analysed according to their allocated
group whatever treatment they received. Descriptive sta-
tistics of the patient characteristics within each treatment
group will be presented (including a summary of the type
of standard anticancer treatment each patient actual
received). The main analysis will compare overall survival
between the two groups using an unadjusted logrank test.
Final analysis will take place when 2047 events (deaths)
have been reported, which is expected to be approxi-
Table 1: Inclusion and exclusion criteria for the FRAGMATIC trial
Inclusion Criteria
Patients meeting the following criteria can be included in the trial:
1. Histopathological or cytological diagnosis of primary bronchial carcinoma (small cell or non-small cell) within the last 6 weeks
2. Age 18 or over
3. ECOG Performance status 0, 1, 2 or 3
4. Willing and able to self-administer LMWH by daily subcutaneous injection or have it administered to them by a carer
5. Willing and able to give informed consent.
Exclusion Criteria
If any of the following criteria apply, patients cannot be included in the trial:
1. Patients with other intrathoracic tumours (e.g. carcinoid, mesothelioma, lymphoma, lung metastases from another primary site)
2. Any previous illness or treatment likely to interfere with protocol treatment or comparisons
3. Clinically apparent brain metastases
4. Patients who have had a haemorrhagic stroke in the last 3 months
5. Haemoptysis of CTC Grade 2 (symptomatic haemoptysis requiring medical intervention) or above
6. Known bleeding disorder
7. Known pregnancy or lactation. Effective contraception is essential for all female patients (of reproductive potential) if sexually active
8. Known hypersensitivity to dalteparin or other low molecular weight heparins and/or heparins 
(e.g. history of confirmed or suspected immunologically mediated heparin induced thrombocytopenia; acute gastroduodenal ulcer; subacute 
endocarditis)
9. Platelet count lower than 100 × 109/L
10. Renal impairment with serum creatinine greater than 150 μmol/L
11. Patients who are currently receiving or have received therapeutic anticoagulation in the last 12 months
12. Patients taking ketorolac (toradol®) - this is a non steroidal anti-inflammatory drug (NSAID) with a well documented risk of causing increased 
bleeding when given with LMWH
13. Patients who at the time of randomisation have a central venous catheter in place and the local practice specifies the use of thromboprophylaxis
14. Any other active malignancy in the last 5 years, except completely treated non-melanoma skin cancer or in-situ carcinoma of cervix. Patients 
with previous malignancies in remission for at least 5 years can be included, provided that there is a clear MDT decision that this is a new primary.Page 7 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:355 http://www.biomedcentral.com/1471-2407/9/355mately 1 year after accrual closes. Kaplan Meier curves and
logrank tests will also be used to compare the two groups
on the secondary outcomes of VTE-free survival and
metastasis-free survival. N.B. It is possible the data for sec-
ondary endpoints (e.g. toxicity) may be mature enough
for analysis and presentation before the main overall sur-
vival primary endpoint. The secondary outcomes of pro-
portions of patients with toxicities and SAEs such as
unexplained death and significant bleeding during the
first six months will be compared using a chi-squared test.
An assessment of compliance with medication in the
dalteparin arm will be made, including an exploration of
predictors of poor compliance. Secondary analysis will
incorporate an assessment of the impact of compliance on
overall VTE-free and metastasis-free survival [42]. The
analysis of QoL, dyspnoea, anxiety, and depression end-
points will use both a subject-specific and group based
approach. The subject-specific approach will use the data
for each individual, the severity of each symptom being
plotted against the assessment time and then the areas
under the curve (AUC) calculated. The AUC is then stand-
ardized by dividing by the number of days between the
first and last assessment, resulting in a standardized AUC
(SAUC) for each patient, for each symptom. The Mann-
Whitney test will be used to compare SAUCs between
treatment arms. The group based approach considers the
proportion of all patients in each treatment group falling
into each symptom category over time. The summary of
this data gives an impression of the severity of each symp-
tom at each specific time point in the trial and is com-
pared between treatment arms using a chi squared test.
The economic evaluation will be in the form of a cost util-
ity analysis from a secondary care perspective. Mean dif-
ferential costs between groups will be estimated. Since
cost data are often skewed, bootstrapping methods will be
used to produce 95% confidence intervals alongside point
estimates. Probabilistic sensitivity analyses will account
for both parameter and decision uncertainty. The EQ-5D
allows estimation of quality adjusted life years (QALYs)
which will be the main effectiveness measure in the eco-
nomic analysis. Between group differences will be esti-
mated using the area under the curve method adjusted for
differences at baseline. In the case of non-dominance,
results will be reported in the form of an incremental cost
effectiveness ratio (ICER) which shows the extra cost of
producing one extra QALY. A cost-effectiveness accepta-
bility curve (CEAC) will be used to calculate 95% confi-
dence intervals for the incremental cost effectiveness
ratios http://www.euroqol.org. No formal subgroup anal-
yses are planned to look at differences in primary and sec-
ondary endpoints between treatment groups within
specific groupings based on patient characteristics. How-
ever exploratory analysis will be conducted to explore
whether there is any consistent benefit from using
dalteparin in different subgroups by creating Hazard Ratio
plots and carrying out tests for interaction/trend based on
chi squared analysis.
Discussion
This Cancer Research UK funded trial will be one of the
biggest lung cancer trials ever conducted in the world and
will be the first to determine whether the addition of
LMWH to routine treatment will be advantages in terms of
overall survival in patients with lung cancer.
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